2022
Epidemiology and outcomes of surgical site infections among pediatric liver transplant recipients
Banach DB, Lopez‐Verdugo F, Sanchez‐Garcia J, Tran A, Gomez‐Llerena A, Munoz‐Abraham A, Bertacco A, Valentino PL, Yoo P, Dembry L, Mulligan DC, Ekong UD, Emre SH, Rodriguez‐Davalos M. Epidemiology and outcomes of surgical site infections among pediatric liver transplant recipients. Transplant Infectious Disease 2022, 24: e13941. PMID: 35989545, DOI: 10.1111/tid.13941.Peer-Reviewed Original ResearchConceptsSurgical site infectionLiver transplant recipientsLiver transplantationBiliary complicationsGraft recipientsTransplant recipientsSite infectionRisk factorsOutcomes of SSIPediatric liver transplant recipientsLong-term graftPediatric liver transplantationRetrospective descriptive analysisPrimary endpointHospital daysPatient agePediatric populationPatient survivalSignificant causeComplicationsPatientsRecipientsOutcomesInfectionIncidence
2021
American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease
Fix OK, Blumberg EA, Chang K, Chu J, Chung RT, Goacher EK, Hameed B, Kaul DR, Kulik LM, Kwok RM, McGuire BM, Mulligan DC, Price JC, Reau NS, Reddy KR, Reynolds A, Rosen HR, Russo MW, Schilsky ML, Verna EC, Ward JW, Fontana RJ, Group F. American Association for the Study of Liver Diseases Expert Panel Consensus Statement: Vaccines to Prevent Coronavirus Disease 2019 Infection in Patients With Liver Disease. Hepatology 2021, 74: 1049-1064. PMID: 33577086, PMCID: PMC8014184, DOI: 10.1002/hep.31751.Peer-Reviewed Original ResearchConceptsMRNA COVID-19 vaccineCOVID-19 vaccineChronic liver diseaseLiver diseaseModerna mRNA COVID-19 vaccinesCoronavirus disease 2019 (COVID-19) infectionExpert panel consensus statementPrevious drug reactionsAdvanced liver diseaseLiver transplant recipientsAvailable COVID-19 vaccinesDisease 2019 infectionSevere hypersensitivity reactionsLocal site reactionsCare of patientsClinical trial participantsHealth care providersLT recipientsTransplant recipientsAdult patientsImmunosuppressed patientsSystemic reactionsHypersensitivity reactionsSite reactionsVaccine efficacy
2020
The Impact of COVID‐19 on Organ Donation, Procurement, and Liver Transplantation in the United States
Merola J, Schilsky ML, Mulligan DC. The Impact of COVID‐19 on Organ Donation, Procurement, and Liver Transplantation in the United States. Hepatology Communications 2020, 5: 5-11. PMID: 33043228, PMCID: PMC7537114, DOI: 10.1002/hep4.1620.Peer-Reviewed Original ResearchLiver transplantationOrgan recoveryOrgan transplantationSevere acute respiratory syndrome coronavirus type 2End-stage liver diseaseOrgan donationExpected excellent outcomesLiver transplant recipientsCoronavirus disease 2019 (COVID-19) pandemicCoronavirus type 2Life-saving procedureCoronavirus disease 2019Disease 2019 pandemicOrgan procurement organizationsHealth care systemTransplant recipientsOrgan failureLiver diseaseDonor evaluationExcellent outcomesDisease 2019New practice paradigmHospital resourcesType 2Particular patientClinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement
Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT. Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID‐19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatology 2020, 72: 287-304. PMID: 32298473, PMCID: PMC7262242, DOI: 10.1002/hep.31281.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusComorbidityConsensusCoronavirus InfectionsCOVID-19COVID-19 Drug TreatmentDrug InteractionsGastroenterologyHumansImmunosuppression TherapyInternship and ResidencyLiver DiseasesLiver TransplantationOccupational HealthPandemicsPatient SafetyPneumonia, ViralPractice Guidelines as TopicSARS-CoV-2Tissue DonorsConceptsLiver transplant providersTransplant providersLiver diseaseHealthcare providersCOVID-19 pandemicExpert panel consensus statementLiver transplant recipientsCare of patientsCoronavirus disease 2019SARS-CoV-2 virusCOVID-19Transplant recipientsIll patientsLiver patientsClinical recommendationsConsensus statementDisease 2019PatientsPatient careDiseaseCareHepatologistsCOVID-19 pandemic impactBest practice advicePractice advice
2018
Successful treatment of primary donor‐derived human herpesvirus‐8 infection and hepatic Kaposi Sarcoma in an adult liver transplant recipient
Fu W, Merola J, Malinis M, Lacy J, Barbieri A, Liapakis AH, Mulligan DC, Yoo PS. Successful treatment of primary donor‐derived human herpesvirus‐8 infection and hepatic Kaposi Sarcoma in an adult liver transplant recipient. Transplant Infectious Disease 2018, 20: e12966. PMID: 30014622, DOI: 10.1111/tid.12966.Peer-Reviewed Case Reports and Technical NotesConceptsHuman herpesvirus 8 infectionHepatic Kaposi sarcomaKaposi's sarcomaTransplant recipientsAdult liver transplant recipientsRegression of KSSplit liver transplantAcute cellular rejectionLiver transplant recipientsSuccessful therapeutic strategiesAllograft functionCellular rejectionLiver transplantSeropositive donorsSuccessful treatmentLiposomal doxorubicinTherapeutic strategiesRecipientsSarcomaInfectionTreatmentImmunosuppressionPatientsMalignancyTransplant
2016
Risks and Epidemiology of Infections After Liver Transplantation
Patron R, Kusne S, Mulligan D. Risks and Epidemiology of Infections After Liver Transplantation. 2016, 215-233. DOI: 10.1007/978-3-319-28797-3_14.Peer-Reviewed Original ResearchInfectious complicationsAppropriate antimicrobial prophylaxisDonor-transmitted infectionLiver transplant recipientsSerious infectious complicationsPrevention of recurrenceEpidemiology of infectionGraft lossHIV coinfectionAntimicrobial prophylaxisLiver transplantLiver transplantationTransplant recipientsOperative timeViral hepatitidesImmune competencePrompt interventionRisk factorsDiligent surveillanceSurgical techniqueSolid organsHigh riskTherapeutic strategiesAnti-infective agentsEarly signs
2013
New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database
Yadav AD, Chang YH, Aqel BA, Byrne TJ, Chakkera HA, Douglas DD, Mulligan DC, Rakela J, Vargas HE, Carey EJ. New Onset Diabetes Mellitus in Living Donor versus Deceased Donor Liver Transplant Recipients: Analysis of the UNOS/OPTN Database. Journal Of Transplantation 2013, 2013: 269096. PMID: 24205434, PMCID: PMC3800575, DOI: 10.1155/2013/269096.Peer-Reviewed Original ResearchDonor liver transplant recipientsAcute cellular rejectionLiver transplant recipientsDeceased donor liver transplant recipientsDDLT recipientsLDLT recipientsTransplant recipientsRisk factorsNew onsetTransplant Network/United NetworkUNOS/OPTN databaseOrgan Sharing databaseIncidence of NODATBody mass indexTimely clinical interventionCellular rejectionDonor diabetesNondiabetic recipientsHepatitis CLiver transplantationRecipient ageSharing databaseMass indexOverall incidencePredictive factors
2012
Polyomavirus JC Urinary Shedding in Kidney and Liver Transplant Recipients Associated With Reduced Creatinine Clearance
Kusne S, Vilchez RA, Zanwar P, Quiroz J, Mazur MJ, Heilman RL, Mulligan D, Butel JS. Polyomavirus JC Urinary Shedding in Kidney and Liver Transplant Recipients Associated With Reduced Creatinine Clearance. The Journal Of Infectious Diseases 2012, 206: 875-880. PMID: 22802433, PMCID: PMC3501156, DOI: 10.1093/infdis/jis469.Peer-Reviewed Original ResearchConceptsJohn Cunningham virusSolid organ transplant recipientsLiver transplant recipientsOrgan transplant recipientsTransplant recipientsBK virusTransplant patientsUrinary sheddingKidney recipientsCreatinine clearanceReduced creatinine clearanceKidney transplant patientsLiver transplant patientsOrgan transplant patientsPolyomavirus BK virusJCV loadLiver recipientsPolyomavirus reactivationRenal dysfunctionSignificant morbidityPatient groupCrCl valuesLiver patientsPatientsKidneyPretransplant Fasting Glucose Predicts New‐Onset Diabetes after Liver Transplantation
Carey EJ, Aqel BA, Byrne TJ, Douglas DD, Rakela J, Vargas HE, Moss AA, Mulligan DC, Reddy KS, Chakkera HA. Pretransplant Fasting Glucose Predicts New‐Onset Diabetes after Liver Transplantation. Journal Of Transplantation 2012, 2012: 614781. PMID: 22461975, PMCID: PMC3306927, DOI: 10.1155/2012/614781.Peer-Reviewed Original ResearchLiving-donor transplantsLiver transplant recipientsIncidence of NODATLiver transplantTransplant recipientsRisk factorsNew-onset diabetesLiver transplantationMELD scoreFasting GlucoseDL increasePoor outcomeMean ageNODATOnset diabetesHCVMultivariate analysisTransplantationTransplantFPGCorticosteroidsDiabetesPatientsIncidenceTwofold increase
2011
A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C
Klintmalm GB, Davis GL, Teperman L, Netto GJ, Washburn K, Rudich SM, Pomfret EA, Vargas HE, Brown R, Eckhoff D, Pruett TL, Roberts J, Mulligan DC, Charlton MR, Heffron TG, Ham JM, Douglas DD, Sher L, Baliga PK, Kinkhabwala M, Koneru B, Abecassis M, Millis M, Jennings LW, Fasola CG. A randomized, multicenter study comparing steroid‐free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transplantation 2011, 17: 1394-1403. PMID: 21850690, DOI: 10.1002/lt.22417.Peer-Reviewed Original ResearchMeSH KeywordsAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedAntiviral AgentsBiopsyChi-Square DistributionDaclizumabDrug Therapy, CombinationFemaleGraft RejectionHepacivirusHepatitis C, ChronicHumansImmunoglobulin GImmunosuppressive AgentsKaplan-Meier EstimateLiver FailureLiver TransplantationMaleMiddle AgedMycophenolic AcidProportional Hazards ModelsProspective StudiesRecurrenceRisk AssessmentRisk FactorsRNA, ViralSurvival RateTacrolimusTime FactorsTreatment OutcomeUnited StatesConceptsAcute cellular rejectionSteroid-free immunosuppressionLiver transplant recipientsHCV recurrenceMycophenolate mofetilTransplant recipientsHCV RNA-positive subjectsHepatitis C virus infectionSevere HCV recurrenceSteroid-free groupC virus infectionChronic hepatitis CGraft survival ratesProportion of patientsLiver biopsy samplesCellular rejectionChronic HCVStandard immunosuppressionSteroid sparingHepatitis CLess diabetesMulticenter trialMulticenter studyPatient survivalArm 1
2004
Significance of Proximal Biliary Dilatation in Patients with Anastomotic Strictures After Liver Transplantation
St. Peter S, Rodriquez-Davalos MI, Rodriguez-Luna HM, Harrison EM, Moss AA, Mulligan DC. Significance of Proximal Biliary Dilatation in Patients with Anastomotic Strictures After Liver Transplantation. Digestive Diseases And Sciences 2004, 49: 1207-1211. PMID: 15387348, DOI: 10.1023/b:ddas.0000037814.96308.7a.Peer-Reviewed Original ResearchConceptsAnastomotic strictureBiliary dilatationDuct sizeDonor bile ductDuct biliary reconstructionProximal biliary dilatationLiver transplant recipientsLevel of obstructionCholangiographic improvementBiliary reconstructionLiver transplantLiver transplantationPosttransplant patientsTransplant recipientsNonresponder groupDuct dilatationRetrospective reviewBile ductCholangiographic imagesResponder groupObstructive cholestasisSignificant obstructionStricturePatientsDuct diameterHepatopulmonary syndrome after living donor liver transplantation and deceased donor liver transplantation: A single‐center experience
Carey EJ, Douglas DD, Balan V, Vargas HE, Byrne TJ, Moss AA, Mulligan DC. Hepatopulmonary syndrome after living donor liver transplantation and deceased donor liver transplantation: A single‐center experience. Liver Transplantation 2004, 10: 529-533. PMID: 15048796, DOI: 10.1002/lt.20127.Peer-Reviewed Original ResearchConceptsDeceased donor liver transplantationDonor liver transplantationHepatopulmonary syndromeLiver transplantationShunt fractionEnd-stage liver diseaseLiver transplant recipientsSingle-center experienceNormal pulmonary functionMean shunt fractionTransplant recipientsMean PaO2Pulmonary functionLiver diseaseSingle centerSupplemental oxygenNatural courseTransplantationHepatic regenerationSmall seriesPatientsLDLTPaO2SyndromeComplicationsHepatitis C Virus Recurrence in Living Donor Liver Transplant Recipients
Rodriguez-Luna H, Vargas HE, Sharma P, Ortiz J, De Petris G, Balan V, Byrne T, Moss A, Mulligan D, Rakela J, Douglas DD. Hepatitis C Virus Recurrence in Living Donor Liver Transplant Recipients. Digestive Diseases And Sciences 2004, 49: 38-41. PMID: 14992432, DOI: 10.1023/b:ddas.0000011599.78222.9e.Peer-Reviewed Original ResearchConceptsDeceased donor transplantationHepatitis C virusLiver transplantationLDLT groupDonor liver transplant recipientsHepatitis C virus recurrenceEnd-stage liver diseaseHCV RNA titersLiver transplant populationLiver transplant recipientsIncidence of rejectionHistological recurrenceChronic hepatitisTransplant recipientsVirus recurrenceDonor transplantationTransplant populationHCV PCRLiver biopsyLiver diseaseAggressive recurrenceSingle pathologistC virusRNA titersInstitutional protocol
1995
QUALITY OF LIFE IMPROVEMENTS AT ONE, TWO, AND FIVE YEARS AFTER LIVER TRANSPLANTATION1,2
Levy M, Jennings L, Abouljoud M, Mulligan D, Goldstein R, Husberg B, Gonwa T, Klintmalm G. QUALITY OF LIFE IMPROVEMENTS AT ONE, TWO, AND FIVE YEARS AFTER LIVER TRANSPLANTATION1,2. Transplantation 1995, 59: 515-518. PMID: 7878756, DOI: 10.1097/00007890-199502270-00013.Peer-Reviewed Original ResearchConceptsQuality of lifeHealth perceptionPosttransplant yearAdult liver transplant recipientsBetter QOLPosttransplant time pointsFirst posttransplant yearLiver transplant recipientsTransplant recipientsAdult patientsOLTxSymptom frequencyYear postDaily livingImpact of healthHealth statusTime pointsPsychological questionnairesHealth interferencePatientsScoresHealth limitationsYearsQUALITY OF LIFE IMPROVEMENTS AT ONE, TWO, AND FIVE YEARS AFTER LIVER TRANSPLANTATION1,2
Levy M, Jennings L, Abouljoud M, Mulligan D, Goldstein R, Husberg B, Gonwa T, Klintmalm G. QUALITY OF LIFE IMPROVEMENTS AT ONE, TWO, AND FIVE YEARS AFTER LIVER TRANSPLANTATION1,2. Transplantation 1995, 59: 515-518. DOI: 10.1097/00007890-199559040-00013.Peer-Reviewed Original ResearchQuality of lifeHealth perceptionPosttransplant yearAdult liver transplant recipientsPost-transplant time pointsBetter QOLFirst posttransplant yearLiver transplant recipientsTransplant recipientsAdult patientsOLTxSymptom frequencyYear postDaily livingImpact of healthHealth statusTime pointsPsychological questionnairesHealth interferencePatientsScoresHealth limitationsYearsOccupational topicsDaily lifeA Comparison Of Treatment With Transjugular Intrahepatic Portosystemic Shunt Or Distal Splenorenal Shunt In The Management Of Variceal Bleeding Prior To Liver Transplantation
Abouljoud M, Levy M, Rees C, Diamond N, Lee S, Mulligan D, Goldstein R, Husberg B, Gonwa T, Klintmalm G. A Comparison Of Treatment With Transjugular Intrahepatic Portosystemic Shunt Or Distal Splenorenal Shunt In The Management Of Variceal Bleeding Prior To Liver Transplantation. Transplantation 1995, 59: 226-229. PMID: 7839445, DOI: 10.1097/00007890-199501270-00013.Peer-Reviewed Original ResearchConceptsTransjugular intrahepatic portosystemic shuntDistal splenorenal shuntIntrahepatic portosystemic shuntDSRS groupVariceal bleedingLiver transplantationSurgical shuntsSplenorenal shuntLiver diseasePortosystemic shuntTIPS groupRole of TIPSPrevious transjugular intrahepatic portosystemic shuntEnd-stage liver diseaseChild-Pugh C patientsIntraoperative hemodynamic measurementsSubsequent transplant procedureAdvanced liver diseaseLiver transplant candidatesLiver transplant recipientsRecurrent variceal bleedingGroup of patientsFirst-line managementBlood flow measurementsComparison of treatments